Its drug regulatory authority India approved today vaccine Three doses of ZyCoV-D DNA against coronavirus of the Zydus Cadila pharmaceutical company, for emergency use, for adults and children aged 12 and over and thus became the sixth vaccine whose use is approved in the country.
As the company announced, it intends to manufacture 100 to 120 million doses of ZyCoV-D per year and has started stockpiling the vaccine.
The pharmaceutical company, registered as Cadila Healthcare Ltd, applied for ZyCoV-D approval on July 1 based on its efficiency rate 66,6% in final stage trials conducted on 28,000 volunteers across the country, as broadcast by APE BPE.
It also stated in July that its first vaccine against Covid-19 was effective against mutations of the new coronavirus, especially the Delta variant.
The Zydus Cadila vaccine, developed in collaboration with the Indian Ministry of Biotechnology and the Indian Council for Medical Research (ICMR), is the secondly a vaccine being developed in India and approved for emergency use in that country after Covaxin by Bharat Biotech.
What technology is used
ZyCoV-D is the first vaccine with plasmid DNA in the world against coronavirus.
Uses one part of genetic material from the virus that gives instructions either as DNA or as RNA for the production of the specific protein that the immune system recognizes and responds to.
How it will be administered
The vaccine is given intradermally (between skin and muscle) with a specialized needleless injector, also became known by the company.
It is recalled that approved coronavirus vaccines are administered intramuscularly with traditional syringes.
* File photo
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
